MAGELLAN LONGEVITY
HomeResearchStudy library › Associations of regular glucosamine use with all-cause and…
Study summary · General aging biology & healthspan

What are the associations between regular glucosamine use and all-cause and cause-specific mortality?

In one paragraph

D-Glucosamine, a prospective cohort study in 495,077 participants (Annals of the Rheumatic Diseases 2020, PMID 32253185) — regular glucosamine use was associated with lower all-cause mortality (HR 0.85), CVD mortality (HR 0.82), cancer mortality (HR 0.94), respiratory mortality (HR 0.73), and digestive mortality (HR 0.74). Scope: 495,077 participants, and the abstract states no limitations.

Source: Annals of the Rheumatic Diseases 2020, PMID 32253185 ↗ · Research map · How Magellan grades evidence · evidence confidence: medium

Annals of the Rheumatic Diseases · 2020 · PMID 32253185 · DOI 10.1136/annrheumdis-2020-217176

Plain-English summary written and published by Magellan Longevity · medical review by Gabriel Radu, DO (physiatrist, NPI 1376861765). We summarize what the paper reported — we did not run this study.

The takeaway

Regular glucosamine use is associated with a lower risk of death from all causes and specific diseases like cancer, CVD, respiratory, and digestive diseases.

The question

What are the associations between regular glucosamine use and all-cause and cause-specific mortality?

What they tested

The study aimed to evaluate the associations of regular glucosamine use with all-cause and cause-specific mortality.

How they did it

This population-based prospective cohort study included 495,077 participants from the UK Biobank, recruited from 2006 to 2010 and followed through 2018. Researchers calculated hazard ratios (HRs) and 95% CIs for all-cause and cause-specific mortality using Cox proportional hazards models, adjusting for potential confounding variables.

What they found

During a median follow-up of 8.9 years, 19,882 all-cause deaths were recorded. Regular glucosamine use was associated with lower all-cause mortality (HR 0.85), CVD mortality (HR 0.82), cancer mortality (HR 0.94), respiratory mortality (HR 0.73), and digestive mortality (HR 0.74). The inverse association with all-cause mortality appeared stronger in current smokers.

Hazard Ratios for Mortality with Regular Glucosamine Use
Values shown: Hazard Ratio
All-cause mortality0.85
CVD mortality0.82
Cancer mortality0.94
Respiratory mortality0.73
Digestive mortality0.74

Hazard ratios indicate the relative risk of mortality for regular glucosamine users compared to non-users, adjusted for confounding variables.

What it means

Regular glucosamine supplementation was associated with lower mortality from all causes, cancer, cardiovascular disease, respiratory disease, and digestive diseases.

Limitations

The abstract does not explicitly state limitations of the study.

Where the published abstract does not list limitations, we say so rather than inventing them. Read the full paper on PubMed before drawing conclusions.

“Regular glucosamine use was associated with significantly lower all-cause, cardiovascular, cancer, respiratory and digestive mortality (all-cause HR 0.73).”— from the published abstract, Annals of the Rheumatic Diseases 2020

The paper at a glance

TitleAssociations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study
JournalAnnals of the Rheumatic Diseases
Year2020
PMID32253185 ↗
DOI10.1136/annrheumdis-2020-217176 ↗
TopicGeneral aging biology & healthspan

Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗

Where Magellan uses this paper

This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.

Glucosamine + Chondroitin (+ MSM)

The evidence for glucosamine and chondroitin in human osteoarthritis is genuinely mixed. The landmark GAIT trial found the pair no better than placebo overall but possibly helpful in the subgroup with moderate-to-severe knee pain, and the MOVES trial found the combination non-inferior to celecoxib;

D-Glucosamine

Evidence on glucosamine for aging-related joint health is genuinely mixed: in the landmark 3-year randomized trial of prescription crystalline glucosamine sulfate (n=212), placebo patients lost significant knee joint space (−0.31 mm) while glucosamine patients did not (−0.06 mm), with symptoms improving on…

D-Glucosamine Sulfate

D-Glucosamine sulfate is a salt of glucosamine, an amino monosaccharide the body synthesizes from…

Check price on Amazon ↗

Osteo Bi-Flex Triple Strength (Glucosamine Chondroitin + Joint Shield)

Osteo Bi-Flex Triple Strength is an oral joint-health supplement whose principal ingredients are…

Check price on Amazon ↗

Glucosamine Chondroitin MSM (with OptiMSM)

Glucosamine, chondroitin sulfate, and methylsulfonylmethane (MSM) are naturally occurring compounds…

Check price on Amazon ↗

Research describes the compound or intervention studied. It is not a claim about any specific product.

Molecules & mechanisms in this paper

Each of these is named in the paper’s own words above. Open the monograph for the full mechanism and its other citations.

Cite this page

These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.

APA
Magellan Longevity. (2026). What are the associations between regular glucosamine use and all-cause and cause-specific mortality? [Plain-English summary of Annals of the Rheumatic Diseases 2020, PMID 32253185, DOI 10.1136/annrheumdis-2020-217176]. Magellan Longevity. https://magellanlongevity.com/study/glu_biobank.html
BibTeX
@misc{magellan_glu_biobank, title = {What are the associations between regular glucosamine use and all-cause and cause-specific mortality?}, author = {{Magellan Longevity}}, year = {2026}, howpublished = {\url{https://magellanlongevity.com/study/glu_biobank.html}}, note = {Plain-English summary of PubMed PMID 32253185; DOI 10.1136/annrheumdis-2020-217176; Annals of the Rheumatic Diseases 2020. Reviewed by Gabriel Radu, DO}, urldate = {2026-08-11} }
Permalink
https://magellanlongevity.com/study/glu_biobank.html

Related studies in the Magellan library

All 25 Magellan summaries on general aging biology & healthspan →

How this summary was made. Every section above restates what the published abstract of PMID 32253185 reports — the question, the design, the numbers, the authors’ own conclusion and their stated limitations. We do not add claims the paper did not make, and we keep negative and no-effect findings in. Magellan’s evidence grades are set from research like this and never from affiliate commissions.

Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →

Educational information, not medical advice. This is a plain-English summary of published research; it is not a treatment recommendation and nothing here is intended to diagnose, treat, cure, or prevent any disease. Individual studies can be wrong, and a single paper rarely settles a question. Talk to your physician before acting on any research, especially if you are pregnant, nursing, or taking medication.